Clean Power Hydrogen (LSE:CPH2) has shipped its first 1MW MFE220 membrane-free electrolyser to a dedicated testing facility for the final phase of factory acceptance testing. The project remains on schedule for site acceptance during the third quarter of 2026, when the company expects to begin generating its first commercial revenues. CPH2 currently has firm orders for four units and is growing its sales pipeline across the UK, Europe, India and the Middle East. It has also entered into several non-binding collaboration agreements linked to zero-carbon initiatives, Middle Eastern energy projects and Indian agritech applications, with potential project sizes of up to 20MW each.
The company has also signed a non-binding agreement with Siemens to explore opportunities to scale manufacturing and accelerate technology development. The collaboration is expected to support product design improvements, process optimisation and broader market deployment. Meanwhile, CPH2’s MFE110 demonstrator unit has achieved independently verified hydrogen purity of 99.999vol% and oxygen purity of 99.7%. These performance levels could allow the company to generate additional revenue through oxygen sales while lowering the lifetime cost of hydrogen production. The company is also developing next-generation 1MW and 5MW systems designed to improve efficiency and potentially enable negative-cost hydrogen production in certain use cases.
The company’s outlook remains weighed down by weak financial fundamentals, including minimal revenue, expanding losses and significant cash burn that has reduced its equity base. Technical indicators offer some support, with the share price showing an upward trend and positive momentum, although a relatively high RSI suggests the possibility of a near-term pullback. Valuation metrics remain difficult to assess given the company’s loss-making status and the absence of dividend yield data.
More about Clean Power Hydrogen PLC
Clean Power Hydrogen plc (CPH2) develops membrane-free electrolyser technology designed to produce high-purity hydrogen alongside above medical-grade oxygen. The company targets decentralised hydrogen production markets, aiming to reduce the levelised cost of hydrogen for applications such as wastewater treatment, curtailed renewable power utilisation, data centres, medical and life sciences, and heavy-duty mobility. Its shares are listed on London’s AIM market under the ticker CPH2.
Leave a Reply